Application status of endoscopic anti-reflux mucosal interventions in the treatment of gastroesophageal reflux disease

Table 1 Anti-reflux mucosectomy treatment for gastroesophageal reflux disease has shown favorable outcomes, %

Ref.	Year	Intervention1	Cases	Effective rate	PPI usage
					Discontinuation	Reduction
Inoue et al[6]	2014	ARMS	10	100	100	0
He et al[8]	2022	L-ARMS	69	85.5	55.1	30.4
Gao et al[9]	2023	ARMS	36	75	25	50
Sumi et al[10]	2021	ARMS	88	69.3	40-50	NA
Wong et al[11]	2020	ARMS	33	90.9	90.9	NA
Sui et al[12]	2022	ARMS	39	89.7	71.8	17.9
Sumi et al[14]	2024	ARMS	88	68.3	42	NA
Lee et al[15]	2024	ARMS-C	115	86	37.5	NA
Yoo et al[16]	2020	ARMS-C	33	93.9	63.6	30.3
Yang et al[17]	2021	ARMS	39	85.7	66.7	19
Hedberg et al[18]	2019	ARMS	19	68.4	68.4	NA
Chou et al[22]	2022	ARMS	11	73.9	56.5	NA
Klimczak and Strzelczyk[24]	2023	ARMS	20	86.7	73.33	NA
Monino et al[32]	2020	ARMS-b	21	76.2	57.1	19.0
Patil et al[33]	2020	ARMS	62	88.7	69.4	19.4
Laquière et al[37]	2022	ARMS	13	91	91	NA
Hu et al[38]	2023	ARMS	12	75	50	25
Average				82.60	63.65	23.44

¹Intervention: Nomenclature of the intervention is based on the designation published by the authors rather than the specific surgical approach.

ARMS: Anti-reflux mucosectomy; L-ARMS: Ligation-assisted anti-reflux mucosectomy; ARMS-C: Anti-reflux mucosectomy with cap-assisted; ARMS-b: Anti-reflux mucosectomy using band ligation; PPI: Proton pump inhibitor; NA: Not available.